Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane)

被引:70
作者
Pilz, H
Oguogho, A
Chehne, F
Lupattelli, G
Palumbo, B
Sinzinger, H
机构
[1] Univ Vienna, Dept Nucl Med, A-1010 Vienna, Austria
[2] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy
[3] Univ Perugia, Inst Nucl Med, I-06100 Perugia, Italy
[4] William Auerswald Atherosclerosis Res Grp ASF Vie, A-1090 Vienna, Austria
关键词
cigarette smoking; oxidation injury; isoprostanes; 8-epi-prostaglandin F-2 alpha;
D O I
10.1016/S0049-3848(00)00249-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Isoprostanes (IP) have been identified as reliable markers of in vivo oxidation injury. Recently, in vascular tissue and blood as well as urine of cigarette smokers, increased IP values have been discovered. We examined 47 adults (26 males, 21 females; aged 30-66 years), admitted to a cardiovascular unit on an outpatient basis, with various risk factors but without any sign of manifestation of atherosclerosis. Refraining from cigarette smoking for a few days resulted in a significant drop of plasma, serum, and urinary 8-epi-PGF(2 alpha). Thereafter, a further continuous decrease was monitored, reaching a steady state after about 4 weeks after quitting cigarette smoking. Prevalues of 8-epi-PGF(2 alpha) were higher, depending on the type and number of risk factors; the decrease after quitting, however, was comparable. These results indicate that exsmokers may rapidly recover from their enhanced in vivo oxidation, (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:209 / 221
页数:13
相关论文
共 27 条
[1]  
Aghajanian AA, 1997, VASA-J VASCULAR DIS, V26, P65
[2]   CARDIOVASCULAR EFFECTS OF LONG-TERM CIGARETTE-SMOKING AND NICOTINE ADMINISTRATION [J].
AHMED, SS ;
MOSCHOS, CB ;
LYONS, MM ;
OLDEWURTEL, HA ;
COUMBIS, RJ ;
REGAN, TJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1976, 37 (01) :33-40
[3]   Isoprostanes - Prostaglandin-like compounds formed in vivo independently of cyclooxygenase - Use as clinical indicators of oxidant damage [J].
Awad, JA ;
Roberts, JL ;
Burk, RF ;
Morrow, JD .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1996, 25 (02) :409-&
[4]   VASCULAR SMOOTH-MUSCLE ACTIONS AND RECEPTOR INTERACTIONS OF 8-ISO-PROSTAGLANDIN-E2, AND E2-ISOPROSTANE [J].
FUKUNAGA, M ;
TAKAHASHI, K ;
BADR, KF .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 195 (02) :507-515
[5]  
FUKUNAGA M, 1995, J CARDIOVASC PHAR S3, V26, P51
[6]   FORMATION OF PGF(2)-ISOPROSTANES DURING THE OXIDATIVE MODIFICATION OF LOW-DENSITY-LIPOPROTEIN [J].
GOPAUL, NK ;
NOUROOZZADEH, J ;
MALLET, AI ;
ANGGARD, EE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 200 (01) :338-343
[7]  
Helmersson J, 1999, PROSTAG LEUKOTR ESS, V61, P203
[8]   Coronary artery constriction by the isoprostane 8-epi prostaglandin F-2 alpha [J].
Kromer, BM ;
Tippins, JR .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (06) :1276-1280
[9]  
KRUPSKI WC, 1991, ANN VASC SURG, V5, P91
[10]   The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets [J].
Leitinger, N ;
Blazek, I ;
Sinzinger, H .
THROMBOSIS RESEARCH, 1997, 86 (04) :337-342